Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.
John M. Burke, MD
Advertisement
Articles by John M. Burke, MD
Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Experts discussed using CD19-targeted agents in patients with various subtypes of diffuse large B-cell lymphoma.
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.
Advertisement
Latest Updated Articles
Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell MalignanciesPublished: September 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy?
2
Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
3
Around the Helix: Cell and Gene Therapy Company Updates – November 5, 2025
4
Quarter Century Update: The Impact of Artificial Intelligence
5
